Timothy P. Rutkowski, Ph.D.

Patent Agent

+1 404 653 6561 +1 404 653 6561
timothy.rutkowski@finnegan.com timothy.rutkowski@finnegan.com

271 17th Street, NW
Suite 1400
Atlanta, GA 30363-6209

vCard

Show Tim's work in

Tim Rutkowski, Ph.D., applies his broad scientiﬁc background in biochemistry, genetics, and neuroscience to patent prosecution and other intellectual property (IP) matters in the biotechnology and life sciences fields.

Tim has multiple years of experience drafting and prosecuting patent applications; conducting freedom-to-operate (FTO) analyses; and developing patentability opinions. Specifically, Tim’s practice has included prosecuting patent applications directed to antibodies and antibody-drug conjugates, cancer genetics, diagnostic methods for treating diseases, gene editing, methods for producing biochemical compounds, and transgenic animals.

Prior to becoming a patent agent, Tim was a post-doctoral fellow at Emory University, where he generated multiple mouse models to study a rare copy number variant, known as the 3q29 deletion, associated with neuropsychiatric disorders in humans. Tim earned his doctorate in genetics from the University of Rochester, where he assessed the role of Notch target genes on early bone development. Through his academic research and education, Tim gained broad scientific training in multiple fields such as behavioral phenotyping in murine models, CRISPR/Cas9-based gene editing, molecular biology, protein purification, and transgenic animals.

Et Cetera

Coauthor. “Behavioral changes and growth deficits in a CRISPR engineered mouse model of the schizophrenia-associated 3q29 deletion,” Molecular Psychiatry, April 11, 2019.
Society for Biological Psychiatry, 2018.
Coauthor. “Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders”, Journal of Neuroscience Research, Nov. 8, 2016.
Coauthor. “3q29 Recurrent Deletion,” Gene Reviews, Sept. 22, 2016.
Coauthor. “HES factors regulate specific aspects of chondrogenesis and chondrocyte hypertrophy during cartilage development,” Journal of Cell Science, June 1, 2016.
Coauthor. “Notch signaling control chondrocyte hypertrophy via indirect regulation of Sox9,” Bone Research, Aug. 11, 2015.
Awarded NIH-sponsored T32 Training Grant through the University of Rochester Center for Musculoskeletal Research, 2013-2015.
Coauthor. “Whole-mount in situ hybridization on murine skeletogenic tissues,” Methods in Molecular Biology (book chapter), 2014.
Coauthor. “Runx1 is critical for PTH-induced onset of mesenchymal progenitor cell chondrogenic differentiation,” PloS One, Sept. 18, 2013.
American Society for Bone and Mineral Research Young Investigator Travel Award, 2012.

Admissions and Education

Admissions

U.S. Patent and Trademark Office

Education

University of Rochester: Ph.D., Genetics, 2015

Roberts Wesleyan College: B.S., Biochemistry, 2008

Tim's Practices

Diligence, Licensing, and Opinions: Freedom to Operate Opinions; Opinions and Counseling
Global IP Enforcement, Litigation, and Trials: Patent Litigation and Trials
Prosecution and Portfolio Management: IP Portfolio Management; Patent Drafting and Prosecution

Tim's Industries

Life Sciences: Biotechnology; Pharmaceutical